Literature DB >> 9753286

AST/ALT ratio > or = 1 is not diagnostic of cirrhosis in patients with chronic hepatitis C.

D W Reedy1, A T Loo, R A Levine.   

Abstract

Medical guidelines for interferon-alpha2a or -alpha2b (IFN-alpha) treatment of chronic hepatitis C virus (HCV) infection depend upon baseline liver histology. A better long-term response to IFN-alpha therapy correlates with less inflammation and absence of cirrhosis. It has been suggested that the presence of cirrhosis in patients with chronic hepatitis C virus infection may be predicted based on an AST/ALT ratio > or = 1. This study was designed to determine if the presence of cirrhosis can be predicted in patients with chronic HCV infection by such a ratio. Seventy-seven patients, including 23 cirrhotics, with chronic HCV infection were studied. Serum ALT, AST, and HCV-RNA levels and hepatic activity index (HAI), reflecting histologic inflammation in all liver biopsies, were assessed. AST/ALT ratios and mean ALT, AST, and HCV-RNA were determined for both cirrhotic and noncirrhotic patients. HAI was correlated with ALT, AST, and HCV-RNA levels, the latter determined by quantitative RT-PCR. The likelihood ratio (LR) and positive predictive value of an AST/ALT ratio > or = 1 for cirrhosis was 7.3 and only 77%, respectively. In cirrhotics vs noncirrhotics, there were no significant differences between mean serum ALT (149 +/- 28 vs 176 +/- 17 units/liter), AST (139 +/- 28 vs 102 +/- 8 units/liter), or HCV-RNA levels (589,160 +/- 147,053 vs 543,915 +/- 75,497 copies/ml), respectively. There was a significant, but clinically weak, correlation between serum ALT and HAI (r = 0.234), and none between HAI and either serum AST or HCV-RNA levels. Our results support the need for a liver biopsy prior to treatment of chronic HCV infection, since the AST/ALT ratio fails to predict accurately the presence of cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9753286     DOI: 10.1023/a:1018888021118

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  16 in total

1.  [Transaminases and histological activity in chronic hepatitis C].

Authors:  P Y Zaugg; M Bernardi; M Schmid; J Havelka; H Bühler
Journal:  Schweiz Med Wochenschr       Date:  1995-04-15

2.  Relationship of aminotransferases to liver histological status in chronic hepatitis C.

Authors:  M M Haber; A B West; A D Haber; A Reuben
Journal:  Am J Gastroenterol       Date:  1995-08       Impact factor: 10.864

3.  Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response.

Authors:  L Pagliaro; A Craxí; C Cammaá; F Tiné; V Di Marco; O Lo Iacono; P Almasio
Journal:  Hepatology       Date:  1994-04       Impact factor: 17.425

4.  Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C.

Authors:  S E McCormick; Z D Goodman; C L Maydonovitch; M H Sjogren
Journal:  Am J Gastroenterol       Date:  1996-08       Impact factor: 10.864

5.  Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: high-titer viremia correlates with advanced stage of disease.

Authors:  D Gretch; L Corey; J Wilson; C dela Rosa; R Willson; R Carithers; M Busch; J Hart; M Sayers; J Han
Journal:  J Infect Dis       Date:  1994-06       Impact factor: 5.226

6.  Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C.

Authors:  M Martinot-Peignoux; P Marcellin; M Pouteau; C Castelnau; N Boyer; M Poliquin; C Degott; I Descombes; V Le Breton; V Milotova
Journal:  Hepatology       Date:  1995-10       Impact factor: 17.425

7.  Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis.

Authors:  A L Williams; J H Hoofnagle
Journal:  Gastroenterology       Date:  1988-09       Impact factor: 22.682

8.  Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group.

Authors:  R Lin; E Roach; M Zimmerman; S Strasser; G C Farrell
Journal:  J Hepatol       Date:  1995-11       Impact factor: 25.083

9.  High-dose interferon-alpha 2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C. A controlled randomized trial.

Authors:  H L Bonkovsky; B D Clifford; L J Smith; C Allan; B Banner
Journal:  Dig Dis Sci       Date:  1996-01       Impact factor: 3.199

10.  Clinical significance of serum hepatitis C virus titers in patients with chronic type C hepatitis.

Authors:  J H Kao; M Y Lai; P J Chen; L H Hwang; W Chen; D S Chen
Journal:  Am J Gastroenterol       Date:  1996-03       Impact factor: 10.864

View more
  12 in total

Review 1.  The de ritis ratio: the test of time.

Authors:  Mona Botros; Kenneth A Sikaris
Journal:  Clin Biochem Rev       Date:  2013-11

2.  Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes.

Authors:  Mohamed Darwish Ahmed Abd Alla; Reham M Dawood; Hassan Abd El-Hafeth Rashed; Galal Farrag; Islam Abdelmawla Emran Ammar; Mohamed Mahmoud Abdel-Halim Mahmoud; Ghada M Salum; Ahmed Mohamed Abdulhamid Altanbouly; Mai A El Meguid; Mostafa K El Awady
Journal:  Arch Virol       Date:  2021-02-03       Impact factor: 2.574

3.  Feasibility of histological grading and staging of chronic viral hepatitis using specimens obtained by thin-needle biopsy.

Authors:  Daniela Petz; Sabine Klauck; Friedrich-Wilhelm Röhl; Peter Malfertheiner; Albert Roessner; Christoph Röcken
Journal:  Virchows Arch       Date:  2003-01-28       Impact factor: 4.064

4.  Noninvasive laboratory tests proposed for predicting cirrhosis in patients with chronic hepatitis C are also useful in patients with non-alcoholic steatohepatitis.

Authors:  Hideki Fujii; Masaru Enomoto; Wakaba Fukushima; Satoko Ohfuji; Mami Mori; Sawako Kobayashi; Shuji Iwai; Hiroyasu Morikawa; Akihiro Tamori; Hiroki Sakaguchi; Yoshihiro Ikura; Makiko Ueda; Norifumi Kawada
Journal:  J Gastroenterol       Date:  2009-04-10       Impact factor: 7.527

5.  Molecular serum markers of liver fibrosis.

Authors:  Tianhui Liu; Xiaoming Wang; Morten A Karsdal; Diana J Leeming; Federica Genovese
Journal:  Biomark Insights       Date:  2012-07-23

6.  Association of laboratory parameters with viral factors in patients with hepatitis C.

Authors:  Bushra Ijaz; Waqar Ahmad; Fouzia T Javed; Sana Gull; Muhammad T Sarwar; Humera Kausar; Sultan Asad; Shah Jahan; Saba Khaliq; Imran Shahid; Aleena Sumrin; Sajida Hassan
Journal:  Virol J       Date:  2011-07-21       Impact factor: 4.099

Review 7.  A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation.

Authors:  Waqar Ahmad; Bushra Ijaz; Sana Gull; Sultan Asad; Saba Khaliq; Shah Jahan; Muhammad T Sarwar; Humera Kausar; Aleena Sumrin; Imran Shahid; Sajida Hassan
Journal:  Virol J       Date:  2011-02-08       Impact factor: 4.099

8.  Quantifying liver cirrhosis by extracting significant features from MRI T2 image.

Authors:  Ming-Hong Hshiao; Po-Chou Chen; Jo-Chi Jao; Yung-Hui Huang; Chen-Chang Lee; Shih-Yu Chao; Li-Wei Lin; Tai-Been Chen
Journal:  ScientificWorldJournal       Date:  2012-06-18

9.  The aspartate aminotransferase-to-alanine aminotransferase ratio predicts all-cause and cardiovascular mortality in patients with type 2 diabetes.

Authors:  Giacomo Zoppini; Vittorio Cacciatori; Carlo Negri; Vincenzo Stoico; Giuseppe Lippi; Giovanni Targher; Enzo Bonora
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

10.  Hepatitis C virus infection influences the S-methadone metabolite plasma concentration.

Authors:  Shiow-Ling Wu; Sheng-Chang Wang; Hsiao-Hui Tsou; Hsiang-Wei Kuo; Ing-Kang Ho; Sheng-Wen Liu; Ya-Ting Hsu; Yao-Sheng Chang; Yu-Li Liu
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.